Around the world, Pulitzer Center grantees are reporting on misinformation related to science, climate change, elections, health issues, and fossil fuels. We believe the best way to counter this ...

In a unique, sweet partnership between two iconic Florida-based brands, TooJay’s Deli, and Lilly Pulitzer have teamed up to create a limited-edition Lemon Coconut Cake, celebrating Lilly Pulitzer’s ...

In a sweet team-up between two iconic Florida brands, TooJay’s Deli and Lilly Pulitzer have created a limited-edition Lemon Coconut Cake to celebrate Lilly Pulitzer’s 65th anniversary. You can now ...

Pulitzer Prize-winning historian Anne Applebaum joins Chris Hayes to discuss how Trump has been talking like dictators of the past—and how this is a new thing for American politics. Oct. 23, 2024 ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE:LLY) for a little while now. My first article about the company, published in ...

A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of drug ...

Lilly's Mounjaro to cost 2,200 Danish crowns per month Wegovy's price ranges from 1,313 to 2,353 crowns per month Denmark's public health system does not reimburse weight-loss drugs The two ...

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

The 35-year-old mom is one of many patients taking a compounded version of tirzepatide produced by a pharmacy while Eli Lilly's brand-name versions, Zepbound and Mounjaro, have been in short supply.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify ...

With its 1-star rating, we believe Eli Lilly’s stock is significantly overvalued compared with our long-term fair value estimate of $580 per share. Our assumptions for overall biopharma GLP-1 ...